Paper - WANFANG MED ONLINE

You Position: Home > Paper

The role of B cell activating factor in the differential diagnosis of usual interstitial pneumonia

( views:356, downloads:332 )

Author:: No author available

Journal Title:: Chinese Journal of Tuberculosis and Respiratory Diseases

Issue:: 7

DOI:: 10.3760/cma.j.issn.1001-0939.2018.07.008

Key Word:: 特发性肺纤维化;自身免疫疾病;受体,B细胞活化因子;Idiopathic pulmonary fibrosis;Autoimmune diseases;B cell activation factor receptor

Abstract： Objective To explore the differential diagnostic role of B cell-activating factor(BAFF) in idiopathic pulmonary fibrosis (IPF) and usual interstitial pneumonia (UIP) associated with autoimmune diseases (AIDs).Methods Plasma levels of BAFF were measured by ELISA method in 23 patients with AIDs-UIP, 34 patients with IPF, and 21 healthy subjects as control.The correlation between plasma BAFF levels and other clinical results from patients was analyzed.Receiver operating characteristics ( ROC) analysis for distinguishing AIDs-UIP from IPF patients was examined and the maximal area under curve (AUC) was found.Results Plasma levels of BAFF were significantly elevated in AIDs-UIP patients and IPF patients compared to healthy subjects (P＜0.001 and P＝0.002, respectively).AIDs-UIP patients had higher level of BAFF than IPF patients ( P ＝0.030).Plasma BAFF levels in AIDs-UIP patients were inversely correlated with pulmonary function results ,including FVC%(r＝-0.435, P＝0.040)and TLC%(r＝-0.449, P＝0.041), as well as DLCO%(r＝-0.491, P＝0.024).When the cut off value of BAFF was set as 1.5 ng/ml to distinguish AIDs-UIP patients from IPF patients , the sensitivity and the specificity was 64.5%and 90.0%, respectively, and the area under ROC curve reached the maximum of 0.784(P＝0.000, 95% CI: 66.3% -90.5%).Conclusions Plasma BAFF levels were significantly higher and inversely correlated with pulmonary function , reflecting the severity of AIDs-UIP patients.Plasma BAFF levels may be a useful marker for distinguishing AIDs-UIP from IPF.

Reference

[1]Lee JS,Maldonado F,Ryu JH,etc.Usual interstitial pneumonia in rheumatoid arthritis-associated interstitial lung disease.[J].2010,35(6).
[2]Stohl,W.,Merrill,J.T.,McKay,J.D.,etc.Efficacy and safety of belimumab in patients with rheumatoid arthritis: A phase II, randomized, double-blind, placebo-controlled, dose-ranging study[J].2013,40(5).
[3]Romagnoli,M.,Nannini,C.,Piciucchi,S.,etc.Idiopathic nonspecific interstitial pneumonia: An interstitial lung disease associated with autoimmune disorders?[J].2011,38(2).
[4]Pierre-Simon, Bellaye,Martin, Kolb.Why do patients get idiopathic pulmonary fibrosis? Current concepts in the pathogenesis of pulmonary fibrosis.[J].2015,13.
[5]Joanna, Groom,Susan L, Kalled,Anne H, Cutler,etc.Association of BAFF/BLyS overexpression and altered B cell differentiation with Sj?gren's syndrome.[J].2002,109(1).
[6]Schneider P,Bossen C.BAFF, APRIL and their receptors: structure, function and signaling.[J].2006,18(5).
[7]Ryffel, Bernhard,Adam, Sylvain Marchand,Wachsmann, Dominique,etc.B cell activating factor is central to bleomycin- and IL-17-mediated experimental pulmonary fibrosis[J].2015,56.
[8]Murray S,Kazerooni EA,Gross BH,etc.Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease.[J].2003,167(10).
[9]Vummidi, Dharshan,Khanna, Dinesh,Wallace, Beth.Management of connective tissue diseases associated interstitial lung disease: a review of the published literature[J].2016,28(3).
[10]C Vitali,S Bombardieri,R Jonsson,etc.Classification criteria for Sj?gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J].2002,61(6).
[11]F C, Arnett,S M, Edworthy,D A, Bloch,etc.The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis.[J].1988,31(3).
[12]Hiroshi, Furukawa,Shomi, Oka,Kota, Shimada,etc.Genetics of Interstitial Lung Disease: Vol de Nuit (Night Flight).[J].2015,9(Suppl 1).
[13]Otterbein,L.,Levesque,M.C.,Kass,D.J.,etc.Plasma B lymphocyte stimulator and B cell differentiation in idiopathic pulmonary fibrosis patients[J].2013,191(5).
[14]Dr. Alfonse T. Masi,Subcommittee For Scleroderma Criteria of the American Rheumatism Association Diagnostic,Therapeutic Criteria Committee.Preliminary criteria for the classification of systemic sclerosis (scleroderma)[J].1980,23(5).
[15]Raghu G,Collard HR,Egan JJ,etc.An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.[J].2011,183(6).
[16]Takezawa K,Drew PA.Pulmonary cryptococcosis and pituitary Cushing's disease.[J].1998,18(5).
[17]Hosoda, Chiaki,Baba, Tomohisa,Hagiwara, Eri,etc.Clinical features of usual interstitial pneumonia with anti-neutrophil cytoplasmic antibody in comparison with idiopathic pulmonary fibrosis[J].2016,21(5).
[18]Furie R,Petri M,Zamani O,etc.A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.[J].2011,63(12).
[19]J. C. Jennette,R. J. Falk,P. A. Bacon,etc.2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides[J].2013,65(1).
[20]Fischer, Aryeh,Antoniou, Katerina M.,Brown, Kevin K.,etc.An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features[J].2015,46(4).
[21]White, Eric S.,Xia, Meng,Murray, Susan,etc.Plasma Surfactant Protein-D, Matrix Metalloproteinase-7, and Osteopontin Index Distinguishes Idiopathic Pulmonary Fibrosis from Other Idiopathic Interstitial Pneumonias[J].2016,194(10).
[22]G S, Cheema,V, Roschke,D M, Hilbert,etc.Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.[J].2001,44(6).
[23]Flaherty,K.R.,Loomis-King,H.,Moore,B.B..Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis[J].2013,13(3).
[24]Aleksander, Lenert,Petar, Lenert.Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.[J].2015,9.
[25]Kono, Masato,Nakamura, Yutaro,Enomoto, Noriyuki.Usual Interstitial Pneumonia Preceding Collagen Vascular Disease: A Retrospective Case Control Study of Patients Initially Diagnosed with Idiopathic Pulmonary Fibrosis.[J].2014,9(4).
[26]Wim A, Wuyts,Alberto, Cavazza,Giulio, Rossi,etc.Differential diagnosis of usual interstitial pneumonia: when is it truly idiopathic?[J].2014,23.
[27]Michael, Donahoe,Vincent G, Valentine,Nydia, Chien,etc.Autoantibody-Targeted Treatments for Acute Exacerbations of Idiopathic Pulmonary Fibrosis.[J].2015,10(6).
[28]Sumikawa,H.,Johkoh,T.,Fujimoto,K.,etc.Pathologically proved nonspecific interstitial pneumonia: CT pattern analysis as compared with usual interstitial pneumonia CT Pattern[J].2014,272(2).
[29]Hoyne, Gerard F.,Elliott, Hannah,Mutsaers, Steven E.,etc.Idiopathic pulmonary fibrosis and a role for autoimmunity[J].2017,95(7).
[30]D'Cruz DP,Cancro MP,Khamashta MA.The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus.[J].2009,119(5).
[31]Mackay F,Schneider P,Rennert P,etc.BAFF AND APRIL: a tutorial on B cell survival.[J].2003,21.
[32]Tsutomu, Hamada,Takuya, Samukawa,Tomohiro, Kumamoto,etc.Serum B cell-activating factor (BAFF) level in connective tissue disease associated interstitial lung disease.[J].2015,15.